Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2017, 35: jco.2017.74.047. PMID: 28692382, PMCID: PMC5846188, DOI: 10.1200/jco.2017.74.0472.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDecision MakingDecision Support TechniquesFemaleHumansConceptsAdjuvant systemic therapyNode-positive breast cancerAdjuvant systemic chemotherapyHigh clinical riskBreast cancerSystemic therapyClinical riskSystemic chemotherapySuch patientsClinical utilityEarly-stage invasive breast cancerClinical Oncology Clinical Practice GuidelineNode-negative breast cancerOncology Clinical Practice GuidelineHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerGood-prognosis populationUse of MammaPrintInvolved lymph nodesGrowth factor receptor 2Invasive breast cancerClinical practice guidelinesClinical risk categories